Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus
Type 1 Diabetes
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus|
- preeclampsia [ Time Frame: 3 years ] [ Designated as safety issue: No ]The development of preeclampsia, defined by hypertension ( > 140/90 mmHg) and proteinuria ( >0,3 g/24 hour).
- preterm delivery [ Time Frame: 3 years ] [ Designated as safety issue: No ]post-partum registration of preterm delivery
- light for gestational age [ Time Frame: 3 years ] [ Designated as safety issue: No ]post-partum registration of "light for gestational age"
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2013|
|Study Completion Date:||October 2015|
|Primary Completion Date:||September 2015 (Final data collection date for primary outcome measure)|
pregestational type 1 diabetes
It is an observational study. No intervention is made.
Hide Detailed Description
Study aim and hypothesis:
To test whether there is a measurable correlation between plasmin/plasminogen, abnormally excreted in the kidneys, and the development of pre-eclampsia in pregnant women with Type 1 diabetes.
1. The amount of proteases ( plasmin/plasminogen ), excreted in urine, predicts development of preeclampsia in pregnant patients with type 1 diabetes.
If a correlation between excreted plasmin/plasminogen, in urine, in patients with type 1 diabetes and development of preeclampsia, are seen, proteases might be used as a marker for pre-eclampsia in this group of patients. Prospectively perhaps also as a marker for disease severity.
In these high risk groups it is possible that outpatient visits could be optimized and thus lower the amount of preterm births.
The study is an observational, longitudinal - prospective study. Women with pregestational type 1 diabetes are included when they show up for their first outpatient pregnancy visit around pregnancy week 9.
Selection of patients:
Patients are selected from Gynecological- obstetric department, Aarhus University hospital - Skejby, and Gynecological- Obstetric department, Odense University Hospital. To be included they must be singleton-pregnant, have turned 18 years and have Type 1 diabetes.
Date of birth, sex, weight, height, BMI, smoking status, current medical treatment, duration of diabetes and parity are registered.
Length of gestation, placental weight, way of delivery (natural birth or cesarean section), umbilical cord pH, apgar score and infant weight are registered post-partum.
Weight, height, BMI, smoking status, microalbuminuria/proteinuria. Blood pressure (systolic, diastolic, mean arterial pressure). Weight of placenta.
Blood test measurements:
Se-creatinine, p-Na+, p-K+. P-plasminogen, P-albumin, Aldosterone.
Measurements in 50 ml "spot urine":
Plasmin, plasminogen, ENaC peptide fragment (analyses in location of development,) Proteolytic activity, Prostatin, Creatinine, Na+, K+, Aldosterone, Albumin
Collection of blood- and spot-urine samples:
Urine-samples are collected in pregnancy week 9-14. Blood pressure is measured. Samples and blood-pressures are re-collected in pregnancy-week 20, 28,32, 36 and perhaps 38.
Following outcomes are observed: Development of preeclampsia, defined by hypertension ( > 140/90 mmHg), and proteinuria ( >0,3 g/24 hour). Preterm delivery and light for gestational age.
Data- analysis methods:
This is an observational longitudinal-prospective study which includes approximately 130 pregnant patients with Type 1 diabetes. Patients are included from Skejby and Odense University Hospitals in cooperation.
Results are evaluated statistically by uni - and multivariate logistic regression analysis.
Population size estimation:
Similar (Danish) observational prospective studies on urine- biomarkers (including albumin) ability to predict preeclampsia/preterm delivery, in patients with pre-gestational type 1 diabetes, have been made. They achieved high significance data with spot-samples of 130 -170 patients. With the participation of two centers it seems realistic and adequately to include 130 patients within the settings of a Ph. D. study. Every year an amount of 50-60 patients are seen in the outpatient ward at Skejby- and Odense University Hospitals (in all approximately 100-120 patients).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01821053
|Gynelogical Obstetrical Department|
|Skejby, Aarhus N, Denmark, 8200|
|Study Director:||Boye L. Jensen, Professor||cardiovascular and renal research department, Odense University Hospital|